troglitazone has been researched along with Cancer of Pituitary in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duan, J | 1 |
| Hu, C | 1 |
| Zhang, Q | 1 |
| Zhu, J | 1 |
1 other study available for troglitazone and Cancer of Pituitary
| Article | Year |
|---|---|
Exploration of the Effects of TGF-
Topics: Animals; Cell Line; Chromans; Male; Matrix Metalloproteinase 9; Pituitary Neoplasms; Rats; Rats, Spr | 2022 |